Skip Page Header

Home > Recommended scope for NPS testing in the United States. Based on trends observed in Q1 2021.

Krotulski, Alex and Papsun, Donna and Mata, Dani and Ellefsen, Kayla and Shoff, Elisa and Shanks, Kevin and Sofalvi, Szabolcs and Kacinko, Sherri and Lewallen, Wayne and Vikingsson, Svante and Logan, Barry (2021) Recommended scope for NPS testing in the United States. Based on trends observed in Q1 2021. Arizona: Society of Forensic Toxicologists.

[img]
Preview
PDF (Recommended scope for NPS testing in the United States)
269kB

The novel psychoactive substance (NPS) landscape is changing rapidly, requiring laboratories to constantly remain abreast of new and emerging drugs locally, nationally, and internationally. To meet individualized needs, laboratories amend existing methods or develop new ones for detection and confirmation. This can be challenging for scientists as information about NPS detections can be regionalized and/or out-of-date, making it difficult to determine which drugs should be prioritized at a given time. NPS Discoveryand the SOFT Designer Drugs Committeehave established the recommendations for NPS scope based on information from extensive collaborations, partnerships, and initiatives which yield national perspectives. Suggested cut-off concentrations or reporting limits (in ng/mL) are listed for each NPS. These values were categorized (i.e., <1, 1-10, and >10 ng/mL) and determined based on currently available quantitative data and/or comparison to structurally similar NPS within the given sub-class

Item Type
Report
Publication Type
International, Guideline
Drug Type
New psychoactive substance
Intervention Type
Harm reduction, Policy
Date
2021
Pages
1 p.
Publisher
Society of Forensic Toxicologists
Place of Publication
Arizona
EndNote
Related (external) link

Repository Staff Only: item control page